PARP inhibitor sensitivity suggests that leukemia cells share the synthetic lethality of combined Brca1 deficiency and PARP inhibition demonstrated in mice with Brca1/Trp53-deficient mammary tumors. This evidence concerns the gene BRCA1 and leukemia.